Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allocade names new CEO
Mr Smith, who brings more than 25 years of experience in leading global sales and marketing organizations for healthcare companies, also serves on Allocade’s board of directors. Prior
Mr Smith, who brings more than 25 years of experience in leading global sales and marketing organizations for healthcare companies, also serves on Allocade’s board of directors. Prior
Previously, Barr has filed an abbreviated new drug application (ANDA) with the FDA for Janssen’s Razadyne (galantamine hydrobromide), 4mg, 8mg and 12mg tablets. Following receipt of notification from
The new system to be installed at Duke University will provide magnetic resonance imaging (MRI) monitoring of cancer treatments in progress as delivered by a BSD Medical system.
Dr Collen will remain chairman of ThromboGenics’s board of directors. This new structure is said to ensure the continuity of ThromboGenics’s senior management. Prior to joining ThromboGenics, Dr
Dave Wentz, CEO of Usana, said: “Entering the Philippines broadens Usana’s international reach and we are excited to offer many of our associate leaders an opportunity to expand
Ms Reinhard previous roles include serving as principal/consultant with dR3 recruiting, resources, results and director of human resources, training, facilities with Spectragraphics/SMS Technologies. Ms Reinhard will be focused
Mr Mason was also recently appointed to the newly created position of group president of North America at Orthofix, and will continue in that role. Mr Mason was
Genentech is developing GDC-0449 under a collaboration agreement with Curis and will be the sponsor of this study. GDC-0449 will be evaluated in approximately 100 patients with ovarian
Takeda has been conducting Phase I clinical studies of Hematide for the treatment of chemotherapy-induced anemia in the US and Japan. However, the companies have decided to suspend
Health Management Associates (HMA) expects to use the proceeds of the sale for general corporate purposes, which includes debt repayment. HMA owns and operates 56 hospitals, with approximately